Gilead Sciences, a leader in HIV and cancer drug development, expects results from over two dozen clinical trials in its 2024 drug pipeline. Profits from its current drugs have propelled Gilead's stock, sparking investor interest. With its acquisition of Immunomedics, Gilead continues to expand its biotech portfolio, positioning itself for future growth.